

# Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) - Pipeline Review, H1 2018

https://marketpublishers.com/r/NB3CEB9C3E3EN.html

Date: March 2018

Pages: 51

Price: US\$ 3,500.00 (Single User License)

ID: NB3CEB9C3E3EN

## **Abstracts**

Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) - Pipeline Review, H1 2018

#### SUMMARY

According to the recently published report 'Nicotinamide Phosphoribosyltransferase - Pipeline Review, H1 2018'; Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) pipeline Target constitutes close to 12 molecules. Out of which approximately 10 molecules are developed by companies and remaining by the universities/institutes.

Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) - Nicotinamide phosphoribosyltransferase (NAmPRTase) is an enzyme encoded by the PBEF1 gene. This protein has also been reported to be a cytokine (PBEF) that promotes B cell maturation and inhibits neutrophil apoptosis.

NAmPRTase catalyzes the condensation of nicotinamide with 5-phosphoribosyl-1-pyrophosphate to yield nicotinamide mononucleotide, one step in the biosynthesis of nicotinamide adenine dinucleotide. The protein is an adipokine that is localized to the bloodstream and has various functions, including the promotion of vascular smooth muscle cell maturation and inhibition of neutrophil apoptosis. It also activates insulin receptor and has insulin-mimetic effects, lowering blood glucose and improving insulin sensitivity.



The report 'Nicotinamide Phosphoribosyltransferase - Pipeline Review, H1 2018' outlays comprehensive information on the Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.

It also reviews key players involved in Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Preclinical and Discovery stages are 1, 8 and 1 respectively.

Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Oncology, Central Nervous System, Cardiovascular, Immunology and Respiratory which include indications Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Age Related Memory Impairment, Amyotrophic Lateral Sclerosis, Depression, Multiple Myeloma (Kahler Disease), Parkinson's Disease, Acute Lung Injury, Breast Cancer, Colon Cancer, Idiopathic Pulmonary Fibrosis, Inflammation, Leukemias, Lung Cancer, Nerve Injury, Non-Hodgkin Lymphoma, Pain, Pancreatic Cancer, Pulmonary Arterial Hypertension, Renal Cell Carcinoma, Sarcomas, Solid Tumor and Waldenstrom Macroglobulinemia.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

#### SCOPE

The report provides a snapshot of the global therapeutic landscape for Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12)

The report reviews Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources



The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) targeted therapeutics and enlists all their major and minor projects

The report assesses Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) targeted therapeutics

#### **REASONS TO BUY**

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic



Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and @Scope



## **Contents**

Introduction

Global Markets Direct Report Coverage

Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing

Factor 1 or NAMPT or EC 2.4.2.12) - Overview

Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing

Factor 1 or NAMPT or EC 2.4.2.12) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing

Factor 1 or NAMPT or EC 2.4.2.12) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing

Factor 1 or NAMPT or EC 2.4.2.12) - Companies Involved in Therapeutics Development

AbbVie Inc

Angelini Group

Aurigene Discovery Technologies Ltd

Calico LLC

Eli Lilly and Co

Genentech Inc

Karyopharm Therapeutics Inc

OncoTartis Inc

Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing

Factor 1 or NAMPT or EC 2.4.2.12) - Drug Profiles

AU-4869 - Drug Profile

**Product Description** 

Mechanism Of Action

R&D Progress

Drug to Inhibit NAMPT for Inflammation and Pain - Drug Profile

**Product Description** 

Mechanism Of Action

**R&D Progress** 

enamptcumab - Drug Profile



**Product Description** 

Mechanism Of Action

**R&D Progress** 

GNE-617 - Drug Profile

**Product Description** 

Mechanism Of Action

**R&D Progress** 

KPT-9274 - Drug Profile

**Product Description** 

Mechanism Of Action

**R&D Progress** 

LSN-3154567 - Drug Profile

**Product Description** 

Mechanism Of Action

**R&D Progress** 

OT-82 - Drug Profile

**Product Description** 

Mechanism Of Action

R&D Progress

P7-C3A20 - Drug Profile

**Product Description** 

Mechanism Of Action

**R&D Progress** 

Small Molecules to Activate NAMPT for Neurological Disorders - Drug Profile

**Product Description** 

Mechanism Of Action

**R&D Progress** 

Small Molecules to Inhibit NAMPT for Oncology - Drug Profile

**Product Description** 

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit NAMPT for Oncology - Drug Profile

**Product Description** 

Mechanism Of Action

**R&D Progress** 

STF-118804 - Drug Profile

**Product Description** 

Mechanism Of Action

R&D Progress



Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) - Dormant Products

Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) - Discontinued Products

Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) - Product Development Milestones Featured News & Press Releases

Sep 08, 2017: Karyopharm Announces Presentation of KPT-9274 Clinical Data at European Society of Medical Oncology 2017 Annual Meeting

Aug 30, 2017: Karyopharm Announces the Presentation of KPT-9274 Clinical Data at the European Society of Medical Oncology 2017 Annual Meeting

Aug 01, 2016: Pharmatek, a San Diego based contract development & manufacturing company, started the development of OT-82 dosage form for human clinical studies Jun 27, 2016: OncoTartis: Initiated OT-82 GLP Toxicology and Safety Pharmacology studies

Jun 22, 2016: Karyopharm Initiates Phase 1 Clinical Trial with KPT-9274

Mar 16, 2016: Karyopharm to Present Data on Oncology drug KPT-9274 at the 2016 American Association for Cancer Research Annual Meeting

Mar 15, 2016: OncoTartis Provides Update on OT-82

Apr 18, 2015: Aurigene to Present its NAMPT Inhibitors Programs at AACR 2015

Mar 30, 2015: Oncotartis in collaboration with scientists from the Children's Cancer Institute of Australia for Medical Research initiated testing of OT-82

Oct 30, 2014: OncoTartis Provides Update on Toxicology study of OT-82

May 16, 2014: Nanosyn, a Santa Clara, CA based chemistry CRO, completed process development for scaling up and manufacturing OT-82 drug candidate on a kilo scale Nov 01, 2013: Novel drug discovery method designed by Stanford scientists

Apr 02, 2013: Aurigene To Present Poster On NAMPT Inhibitor Program At AACR 2013 Appendix

Methodology

Coverage

Secondary Research

**Primary Research** 

**Expert Panel Validation** 

Contact Us

Disclaimer



# **List Of Tables**

#### LIST OF TABLES

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Indications, H1 2018

Number of Products under Development by Indications, H1 2018 (Contd..1), H1 2018

Number of Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Number of Products under Investigation by Universities/Institutes, H1 2018

Products under Investigation by Universities/Institutes, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Pipeline by AbbVie Inc, H1 2018

Pipeline by Angelini Group, H1 2018

Pipeline by Aurigene Discovery Technologies Ltd, H1 2018

Pipeline by Calico LLC, H1 2018

Pipeline by Eli Lilly and Co, H1 2018

Pipeline by Genentech Inc, H1 2018

Pipeline by Karyopharm Therapeutics Inc, H1 2018

Pipeline by OncoTartis Inc, H1 2018

Dormant Projects, H1 2018

Discontinued Products, H1 2018



# **List Of Figures**

#### LIST OF FIGURES

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Top 10 Indications, H1 2018

Number of Products by Mechanism of Actions, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1 2018

#### **COMPANIES MENTIONED**

AbbVie Inc

Angelini Group

Aurigene Discovery Technologies Ltd

Calico LLC

Eli Lilly and Co

Genentech Inc

Karyopharm Therapeutics Inc

OncoTartis Inc



#### I would like to order

Product name: Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor

1 or NAMPT or EC 2.4.2.12) - Pipeline Review, H1 2018

Product link: https://marketpublishers.com/r/NB3CEB9C3E3EN.html

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

# **Payment**

First name:

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <a href="https://marketpublishers.com/r/NB3CEB9C3E3EN.html">https://marketpublishers.com/r/NB3CEB9C3E3EN.html</a>

To pay by Wire Transfer, please, fill in your contact details in the form below:

Last name:	
Email:	
Company:	
Address:	
City:	
Zip code:	
Country:	
Tel:	
Fax:	
Your message:	
	**All fields are required
	Custumer signature

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <a href="https://marketpublishers.com/docs/terms.html">https://marketpublishers.com/docs/terms.html</a>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

